Lexicon Pharmaceuticals Inc. (LXRX)
LXRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/0001062822-26-000050-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LXRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001062822 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $49.8M |
| Net income | -$50.3M |
| Operating income | -$48.9M |
| Net margin | -101.1% |
| Operating margin | -98.2% |
| Revenue growth | +60.2% |
| Cash | $34.3M |
| Total assets | $185.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 15.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $44.1M cash; operating cash flow -$12.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 445,234,571 (2026-11-02); 363,398,680 a year earlier; 244,924,695 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns | Latest 2026-02-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Houston, Texas, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $2.7M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $11.3M | -$14.0M | -$8.1M | $44.1M | $51.9M | $38.5M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $692K | -$31.8M | -$9.2M | $40.9M | $51.4M | $41.5M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $21.1M | -$1.0M | -$14.7M | $38.1M | $49.7M | $69.6M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $5.5M | -$15.5M | -$17.2M | $34.3M | $54.0M | $49.8M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $14.2M | -$12.8M | -$23.8M | $49.7M | $56.5M | $70.9M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $28.9M | $3.3M | $17.0M | $21.4M | $56.1M | $58.4M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $1.3M | -$25.3M | -$43.8M | $62.9M | $100.7M | $31.2M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $26.6M | -$33.8M | -$21.5M | $66.7M | $100.3M | $31.1M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-06 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy DEF 14A | DEFA14A | 2026-03-16 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.6% |
| 1 month | +11.2% |
| 3 months | -23.5% |
| Year to date | +55.7% |
| 1 year | +24.3% |
| From 52-week high | -32.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ORIC | Oric Pharmaceuticals Inc. | $7.52 | -4.33% | $779.5M |
| IVA | Inventiva S.A. American Depository Shares | $3.32 | -9.78% | $784.5M |
| ARDX | Ardelyx Inc. | $3.07 | -0.65% | $771.7M |
| COLL | Collegium Pharmaceutical Inc. | $25.43 | +0.43% | $790.2M |
| OBX | Obsidian Therapeutics Inc. | $12.36 | -1.59% | $763.5M |
| IRWD | Ironwood Pharmaceuticals Inc. | $4.85 | +0.41% | $802.9M |
| SNDX | Syndax Pharmaceuticals Inc. | $9.13 | -3.39% | $821.6M |
| RIGL | Rigel Pharmaceuticals Inc. | $43.73 | -1.64% | $823.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier